Forward Pharma awaits judgment: All opportunities are still open
From an outside perspective, it may seem like Forward Pharma is just waiting for judgment in a European patent interference case. However, CEO Claus Bo Svendsen maintains that all opportunities remain open for the company.
)
Forward Pharma has long been an outsider in Danish life science, and the company has only become more atypical as time goes by.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Forward Pharma loses European patent case
For abonnenter
Forward Pharma loses patent case to Biogen
For abonnenter
